ISCT Open Access Webinars

Considerations for Cryopreservation Practices in Cell Therapy Fill/Finish Processes 

10-26-2021 20:14

Webinar Description:

This webinar will discuss the considerations involved in making decisions that impact the cryopreservation needs of a cell therapy drug product encountered during process development. We will discuss the challenges of scale in cell therapy, the gaps in automation and standardization in cryopreservation processes, and showcase technologies that address fill/finish obstacles in the cryopreservation of autologous and allogeneic cell therapies.

Considerations for Cryopreservation Practices in Cell Therapy Fill/Finish Processes

An ISCT Process and Product Development Webinar
Part 2 of 6 of the ISCT PPD Webinar Series

Sponsored in part by: 

Chaired By: 

Samuel Molina, PhD
Sr. Scientist – Advanced Therapies
West Pharmaceutical Services
Exton, PA, USA

Dr. Molina is the Cell and Gene Therapy SME in the Applied Life Sciences & Technology Scouting R&D organization at West. He came to West with 8 years of hands-on knowledge in primary human cell manufacturing at both academic and commercial scale, having developed processes and products for the 3D human primary cell models and immunology and cell therapy research markets.


Lesley Chan, PhD
Associate Director of Process Sciences & Innovations, bluebird bio
Cambridge, MA, USA

Lesley leads a team of process development scientists with a goal of developing scalable and robust manufacturing processes for gene-modified hematopoietic stem and progenitor cell therapies. She also leads cross-functional initiatives to implement these next-generation manufacturing processes into the clinic.

Steven Doares, PhD, SVP
US Manufacturing & Site Head
Cellectis Biologics
Raleigh, NC, USA

Steve leads the functional teams at Cellectis’ new drug substance/drug product manufacturing plant for allogeneic, off-the-shelf T-cell therapies (UCARTs), located in Raleigh, NC. This state-of-the-art facility was designed to meet both clinical and future commercial drug product production capacity needs for Cellectis’ portfolio of immune-oncology UCART programs.

Dalip Sethi, PhD
Director of Scientific Affairs
Terumo Blood and Cell Technologies
Denver, CO, US

Dr. Sethi currently serves as the scientific and clinical development lead for the Cell Therapy Technologies portfolio at Terumo BCT. He holds a doctorate degree and conducted post-doctoral studies at Thomas Jefferson University, PA, USA. Prior to Terumo BCT, Dalip was engaged in the development of technologies & methods for use in cell therapy applications. Throughout his career, Dalip has authored multiple scientific publications and is a co-inventor on several patents & patent applications.

Jean-Sebastian Parisse, PhD
Commercial Director
Aseptic Technologies
Belgium, EU

Dr. Parisse manages and directs the global sales efforts of Aseptic Technologies; accelerating growth and creating tighter connections between customer requirements and innovation, along with increased service levels, with a special attention to immunotherapies since 2009.



1 Files

Related Entries and Links

No Related Resource entered.